17,261 trials
Schizophrenia · Schizophrenia Schizoaffective
Primary: Change in Globus Pallidus Interna (GPi) Functional Connectivity During PLIFUS Intervention Visit
Seizures
Primary: Response Ratio (RRatio) — -24.06; -22.45; -25.90; -24.19 RRatio — p==0.986
Alcohol Use Disorder
Primary: Change in Blood Oxygen Level Dependent (BOLD) fMRI Signal for Alcohol Versus Non-alcohol Stimuli — 0.267390; 0.040281; 0.058670; -0.069048 BOLD response
Endometrial Cancer · Uterine Carcinosarcoma
Primary: Treatment Related Overall Response Rate — 30 participants
Non-small Cell Lung Cancer
Primary: The Percentage of Patients That Respond to Treatment — 46; 29 percentage of patients
Phelan-McDermid Syndrome
Primary: Safety and Tolerability — 17; 17; 1; 3 Participants
Idiopathic Pulmonary Fibrosis
Primary: Number of Participants Who Experienced at Least One Treatment Emergent Adverse Events (TEAEs) — 35; 26 Participants
Breast Cancer
Primary: Overall Response Rate (ORR) Per RECIST1.1 — 7 Participants
CMT
Primary: Safety of Intramuscular (IM) Injections of Engensis in Participants — 1; 1; 1; 1 Participants
Major Depressive Disorder
Primary: Change From Baseline in Hamilton Depression Rating Scale (HAMD-17) Total Score at Weeks 8 — -9.0; -7.4 Scores on a scale — p=0.121
Malignant Glioma
Primary: Maximum Tolerated Dose (MTD) of MK-3475 When Combined With MLA - Phase I Only — 200 mg
Penile Cancer
Primary: Objective Response Rate (ORR) — 3; 15 Participants
Pancreatic Cancer · Metastatic Castration-resistant Prostate Cancer · Bladder Cancer
Primary: To Determine the Safety and Tolerability of NGM120 in Subjects — 1; 6; 6; 17 Participants
Advanced Solid Tumors
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) — 100; 100; 100; 100 percentage of participants
Amyotrophic Lateral Sclerosis
Primary: Treatment-Emergent Adverse Events in More Than 2 Subjects Overall by System Organ Class and Preferred Term — 3; 3; 0; 2 Participants